Ani Pharmaceutic SEC Filings

Form 144 notice for ANI Pharmaceuticals, Inc. (ANIP) reports a proposed sale of 7,292 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $692,270.40 and stated approximate sale date of 09/03/2025. The filer identifies prior restricted stock acquisitions of 3,000 shares on 04/27/2023 and 4,292 shares on 03/23/2022, both received from the issuer, and discloses a sale during the past three months of 5,421 shares for $486,406.81 on 08/20/2025. The form includes the standard representation that the seller is not aware of any undisclosed material adverse information.

Insider sale disclosed on Form 4 for ANI Pharmaceuticals, Inc. (ANIP). The filing shows that Matthew J. Leonard, reported as a director, sold 2,528 shares of ANIP common stock on 08/25/2025 at a reported price of $90.62 per share. After the sale, Mr. Leonard beneficially owned 6,864 shares, reported as direct ownership. The Form 4 was signed by attorney-in-fact Meredith W. Cook on 08/26/2025. No derivative transactions or additional remarks are included in the filing.

ANI Pharmaceuticals (ANIP) Form 144 notice shows a proposed sale of 2,528 restricted common shares by or for an identified person through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $229,075.98 and an approximate sale date of 08/25/2025. The filing states those shares were acquired as restricted stock from the issuer on 08/21/2025 and paid for on that date. The form also discloses a separate sale by Matthew Leonard of 6,937 common shares on 08/18/2025 with gross proceeds of $611,644.31. The filer certifies they have no undisclosed material adverse information.

Krista Davis, SVP and Chief HR Officer of ANI Pharmaceuticals, Inc. (ANIP), reported the sale of 1,763 shares of ANI common stock on 08/22/2025. The shares were sold in multiple trades at prices ranging from $91.01 to $91.19, with a weighted average sales price reported as $91.10. After the transaction, Ms. Davis beneficially owned 62,896 shares. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 08/25/2025. The filing identifies the reporter as an officer (SVP, Chief HR Officer).

ANI Pharmaceuticals insider sale by Shanmugam Muthusamy — The filing shows the company director and Head of R&D/COO-Novitium Ops executed sales of ANI Pharmaceuticals (ANIP) common stock on August 20–21, 2025. On 08/20/2025 the reporting person sold 47,012 shares at a weighted average price of $90.27, and on 08/21/2025 sold 52,988 shares at a weighted average price of $90.44. After these transactions the reporting person retained indirect beneficial ownership of 431,920 shares through Esjay LLC and an additional 5,000 shares held by SS Pharma LLC, with voting and dispositive power over those LLC-held shares. The form is signed by attorney-in-fact Meredith W. Cook.

ANI Pharmaceuticals' Schedule 13D/A reports that Meridian Venture Partners II entities and affiliated persons beneficially own a combined 1,034,570 shares of ANI common stock, representing 4.8% of the class. The filing breaks ownership across Meridian Venture Partners II GP, L.P., Meridian Venture Partners II, L.P., Meridian Venture Partners II, Co., and Robert E. Brown, Jr., with shared voting and dispositive power over 1,014,381 shares held by the Meridian entities and sole voting/dispositive power over 20,189 shares held directly by Mr. Brown.

The statement provides the issuer's principal office address and is signed by Robert E. Brown, Jr. as of 08/21/2025. No additional transaction details, intentions regarding the investment, or legal proceedings are disclosed in the provided excerpt.

Form 144 filed for ANIP insider sales The filing notifies proposed and recent sales of ANI Pharmaceuticals common stock by an insider. A proposed sale of 52,988 shares through Merrill Lynch on NASDAQ is listed with an aggregate market value of $4,792,058.06 and an approximate sale date of 08/21/2025. The shares were acquired on 11/19/2021 in a company buyout and listed as a compensatory payment. The filing also reports three recent sales by Muthusamy Shanmugam on 08/14/2025, 08/15/2025, and 08/20/2025 totaling 147,012 shares with gross proceeds reported for each sale. The filer certifies no undisclosed material adverse information.

ANI Pharmaceuticals Form 144 notice reports a proposed sale of 47,012 shares of common stock through Merrill Lynch on NASDAQ with an aggregate market value of $4,243,702.53 and an approximate sale date of 08/20/2025. The securities were acquired on 11/19/2021 as a company buyout from ANI Pharmaceuticals and the indicated payment is a compensatory payment. The filing also lists recent sales by the same seller on 08/14/2025 (47,010 shares) and 08/15/2025 (52,990 shares). The notice contains the seller's certification that they are unaware of undisclosed material adverse information about the issuer.

Jeanne A. Thoma, a director of ANI Pharmaceuticals, Inc. (ANIP), reported two open-market sales of the issuer's common stock on 08/18/2025. The Form 4 shows a sale of 6,865 shares at a weighted-average price of $89.76 and a sale of 14,675 shares at a weighted-average price of $88.87, both reported as direct beneficial ownership dispositions. The explanatory remarks state the first block traded between $89.75 and $89.90 and the second between $88.74 and $89.39; the signature date on the filing is 08/20/2025. The form lists post-transaction beneficial ownership of 38,080 shares and 23,405 shares on the respective lines, and indicates the reporting person files as an individual and is a director of the issuer.